No Data
No Data
Ladenburg Thalmann Maintains Viridian Therapeutics(VRDN.US) With Hold Rating
Ladenburg Thalmann analyst Michael Higgins maintains $Viridian Therapeutics(VRDN.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 34.3% and a total average return
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $30 to $46
On Jun 12, major Wall Street analysts update their ratings for $Viridian Therapeutics(VRDN.US)$, with price targets ranging from $30 to $46.Needham analyst Serge Belanger maintains with a buy rating,
Express News | Wolfe Research Initiates Coverage On Viridian Therapeutics With Outperform Rating
Viridian Therapeutics Price Target Maintained With a $30.00/Share by Needham
Viridian Therapeutics Price Target Maintained With a $30.00/Share by Needham
Viridian Gains After R&D Update; Wolfe Starts at Outperform
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Health care stocks were mixed premarket Tuesday, with the Health Care Select Sector SPDR Fund (XLV) was 0.1% higher and the iShares Biotechnology ETF (IBB) was down 0.5% recently. Viridian Therapeutic
No Data